# 

## Highlights in 2024

## Achievements

To date, a total of 14 deliverables have been submitted, and 10 milestones have been achieved. In 2024, GENEGUT has achieved significant results across all work packages and RP1 has been approved.

#### **WP1**

- Libraries of novel biocompatible materials
- Quantification of formulation stability in vitro
- ✓ Development of RNA NP formulations to withstand simulated intestinal fluids

#### WP4

- ✓ Submission of pig study to UCC ethics committee
- ✓ Establishment of CD ileal 3D model under static conditions

#### WP2

- Development & characterisation of an intestinal 3D organoid model
- ✓ Assessment of initial delivery and efficacy of siRNA/mRNA in various cell models

#### WP5

✓ Literature review on regulatory & HTA context, pathways & requirements for RNA therapeutics

#### **Deliverables & Milestones**



#### WP3

- In vitro biorelevant media simulating IBD's conditions
- Demonstration of ileocaecal release with capsule technology
- ✓ In vivo pig study to define the maximum capsule size

#### WP6

- ✓ Interim Impact Report I
- Conference participation

#### WP7

- Continuous project monitoring
- ✓ RP1 approved

### Collaboration



GENEGUT consortium in Porto (Portugal) in June 2024

The close collaboration within the GENEGUT consortium continued throughout 2024, during which it gathered for three General Assembly (GA) meetings, one of which was hosted in person in <u>Porto, PO</u> in June 2024. Shortly after, a very successful RP1 review meeting with the EC took place.

The Scientific Advisory Board was present at the 6<sup>th</sup> and latest GA meeting in December 2024 and provided very positive and encouraging feedback.

In addition, GENEGUT's MST+PI board met four times during the year to monitor the project's progress and foster WP collaboration.





Funded by the European Union (GA 101057491) and supported by the UK's innovation agency, Innovate UK. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

# 

## Communications

### **Publications**

Three GENEGUT related articles were published in peer-reviewed journals:

Trends in 3D models of inflammatory bowel disease

State-of-the-art and future perspectives in ingestible remotely controlled smart capsules for drug delivery: A GENEGUT review

Establishment of a 3D multilayered in vitro model of inflammatory bowel disease


### Training

With the successful completion of Deliverable D6.5, GENEGUT provided initial training materials created to empower Inflammatory Bowel Disease (IBD) patients with knowledge of advanced therapies and RNA-based medicines. The pilot training lecture was delivered by the GENEGUT coordinator, Prof. Caitriona O'Driscoll (UCC), and recorded by the EFCCA Academy.

855

Users on

Milestones in 2025







at Uppsala University

Funded by the European Union (GA 101057491) and supported by the UK's innovation agency, Innovate UK. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

in preparation